At last, update at CYGX website management
Kurt L. Berens – , Product Development
Mr. Berens has ten years research and development experience in ethical drugs and medical devices. Mr. Berens has been a collaborator on projects in academia and was most recently the Manager of the Cellular and Biomedical Section at NASA-Johnson Space Center. He was a Senior Project Manager for Texas Biotechnology for six years, Mr. Berens was part of a development team that was successful in obtaining FDA approval for Argatroban®.
Mr. Berens received his Bachelor's degree at the University of Minnesota followed by doctoral studies in pharmaceutics at the University of Houston.
Key Employees
Xin-Xing Tan, PhD - Senior Research Scientist
Dr. Tan earned his Ph.D. in Biochemistry from the Chinese Academy of Science, Shanghai, China. He was an NIH sponsored post-doctoral fellow at Rice University, Houston. He has authored or co-authored twenty scientific published papers. Dr. Tan joined CytoGenix in 2002, is co-inventor of an anti-bacterial technology developed in the Company's laboratory.
Harilyn McMicken, BS, MT(ASCP) – Senior Laboratory Director
Harilyn W. McMicken graduated from Abilene Christian University and University of Texas at Galveston. She has done postgraduate work at the University of Texas School for Biomedical Sciences in Houston, Texas. Prior to her employment, Ms McMicken was Senior Research Assistant for 23 years in the Department of Pediatrics at Baylor College of Medicine. Her responsibilities and expertise lie in the areas of molecular biology and laboratory and personnel management.
Frederic Kendirgi, PhD – Research Scientist
Dr. Kendirgi has broad experience in eukaryotic gene expression as well as developing assays for protein detection/function and expression vectors in eukaryotic systems. He earned his M.Sc. in Virology and Immunology in 1995 from the University of Quebec (INRS-Institut Armand-Frappier) Laval, Canada and his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary, Calgary Alberta, Canada in 2000. Subsequently, he joined the laboratory of Dr. S.R. Wente as post-doctoral scientist at Washington University in St. Louis and Vanderbilt University, Nashville. Dr. Kendirgi has authored, co-authored or presented 10 scientific abstracts at national and international meeting and 5 scientific papers. He joined Cytogenix research and development team in October 2004.
Scientific Advisory Board
Our Scientific Advisory Board is comprised of leading scientists and clinician authorities in the fields of dermatology, cancer research and gene therapy.
Yin Chen, PhD, Chairman of SAB
Dr. Chen earned this Ph.D. in Molecular Biology & Biochemistry at the University of Maine in 1996. Subsequently, he was a post-doctoral fellow at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. In 1999, he joined InGene, Inc. of St. Louis as senior research scientist and then CytoGenix, as chief research scientist in February 2000. He is one of co-inventors of our company's proprietary ssDNA expression systems.
Cy A. Stein, MD PhD
Peter Glazer, MD, PhD
Dr. Glazer holds academic degrees from Harvard (BA), Oxford (MS), and Yale (Ph.D.) and a Medical Degree from Yale University School of Medicine where he is an Associate Professor of Therapeutic Radiology and Genetics.His research interests include gene targeting and gene therapy, genetic instability in cancer, mutagenesis, and DNA repair.
Madeleine Duvic, MD
Dr. Duvic is a Professor of Medicine Chief, Section of Dermatology, and Associate Medical Director of the Melanoma Skin Center at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Duvic received her B.A. from Rice University, magna cum laude, as a National Merit Scholar and her M.D. from Duke University Medical School.
Samuel Kaplan, Ph. D.
Dr. Kaplan is Professor and Chairman of the Department of Microbiology of the University of Texas, Houston Medical School. His scientific and academic career spans four decades and several continents. He is Chairman of the publications board of the American Society of Microbiology, publishers of eleven of the world's premier biological sciences journals. Recognized by his peers, he is the recipient of twelve honorary awards. He has authored over 200 scientific papers and written several chapters of electronic educational texts.
Dr. Kaplan earned his bachelor's degree from Cornell University, his masters from Yale and his doctorate in molecular genetics from the University of California San Diego. He completed two years of post-doctoral training at Cambridge University. He joined the faculty of University of Illinois - Urbana in 1967 and moved through the institution's academic ranks to the position of professor and director of the Biotechnology Center in 1987. In 1989, he was appointed Chairman of the Department of Microbiology at University of Texas Houston Medical School.
Board of Directors
Malcolm Skolnick, PhD, JD – Chairman/President and CEO
Frank Vazquez –Executive Vice President/COO
Lawrence Wunderlich – Chief Financial Officer, Treasurer, Secretary
Cy A. Stein, MD PhD
Brown University (BA), Stanford University (PhD in Organic Chemistry), Albert Einstein College of Medicine (MD), and New York Hospital-Cornell Medical Center (Internship and Residency in Internal Medicine). Dr Stein was a Clinical Associate and Senior Staff Fellow at The National Cancer Institute, Bethesda, Maryland.He is currently an Associate Professor of Pharmacology and Clinical Medicine at Columbia University, College of Physicians and Surgeons, in New York.
In addition to his clinical and faculty activities, he is Co-Editor-in-Chief of Antisense and Nucleic Acid Drug Development, sits on 7 Editorial Advisory Boards, including Nucleic Acids Research, serves on 8 Scientific Advisory Boards including Genta (Berkeley Heights, NJ), Targent (New York, NY), A3D (Heidelberg, Germany), and is an Ad hoc Reviewer for over twenty peer review journals. Dr Stein is the author of 97 peer review journal articles.He has written 56 book chapters, reviews and editorials, and he has six patents issued and four patents pending.
Scott E. Parazynski M.D
Dr. Parazynski is a graduate of Stanford University and Stanford Medical School and pursued clinical training at the Brigham and Women's Hospital (Boston, MA) and emergency medicine residency training in Denver, CO. He has published articles in the field of space physiology and has expertise in human adaptation to stressful environments. Dr. Parazynski is a member of the Aerospace Medical Association, the American Society for Gravitational and Space Biology. He has received numerous special honors, including the National Institutes of Health Pre-doctoral Training Award in Cancer Biology, NASA Graduate Student Researcher's Award and Research Honors Award from Stanford Medical School.
Dr. Parazynski has been an astronaut since 1992 and has logged over 262 hours in space. He first flew in 1994 on the Atmospheric Laboratory for Applications and Science (ATLAS-3) mission, which was part of an on-going program to determine the Earth's energy balance and atmospheric change over an 11-year solar cycle. During this mission, he and his crewmates also evaluated the Interlimb Resistance Device, a free-floating exercise he developed to prevent musculoskeletal atrophy in microgravity.
John J. Rossi, PhD
Associate Director for Laboratory Research, City of Hope Comprehensive Cancer Center
John J. Rossi, PhD came to City of Hope (COH) in 1980 as an assistant research scientist in the Department of Molecular Genetics. He was promoted to chairman of the Division of Biology in 1992. In 1993, COH bestowed its highest honor upon him by naming him to its Gallery of Medical and Scientific Achievement for his pioneering work at the molecular level in the battle against AIDS and other major diseases. In 1998 Dr. Rossi was appointed as the Dean of the City of Hope Graduate School of Biological Sciences.
Dr. Rossi is a world-renowned expert in ribozymes (molecular scissors). Dr. Rossi's major contributions to science have been through understanding the processing and metabolism of RNA inside the cell. Ribozymes, also known as catalytic RNA and "molecular scissors", are molecules that can break down nucleic acid inside a cell, thus they can be used to cut out "bad" genetic information and splice in "good" material. One of his most notable projects is in the area of ribozyme research in AIDS. He led the research team that first suggested applying ribozymes to treat HIV. His research in molecular genetics and microbiology has earned eight patents and has served as the basis for more than 120 scientific papers.
Born and raised in Washington D.C., Dr. Rossi received his bachelor's degree from the University of New Hampshire and earned his doctorate at the University ofConnecticut. He completed four years of post PhD training at Brown University in Providence, Rhode Island before coming to COH.
Raymond L. Ocampo Jr.
Raymond L. Ocampo Jr. is a lawyer, businessman and author who has served as a member of the board of directors and board of trustees of numerous corporate and nonprofit organizations. He currently serves on the boards of PMI Group, Inc. (PMI) and Pinpoint Solutions Corporation. He previously served on the boards of Vantive Corporation and Teamscape Corporation (before their separate acquisitions by PeopleSoft, Inc.), Spruce Technologies, Inc. (before its acquisition by Apple Computer, Inc.), Syncronex, Inc., Blackboard Entertainment, Inc. and HolaMujer.com. He has served on the advisory boards of Advanced Mobile Solutions and FindLaw.com and In-Q-Tel, the venture capital arm of the Central Intelligence Agency.
Mr. Ocampo retired in November 1996 as Senior Vice President, General Counsel & Secretary at Oracle Corporation, the world's second largest software company, after serving as its chief legal counsel for more than a decade. During his tenure at Oracle Corporation, the company's annual revenues grew from $50 million in 1986 to $5 billion in 1996. Before joining Oracle Corporation in 1986, Mr. Ocampo specialized in antitrust and complex litigation with various law firms in San Francisco (1976-86) and taught professional responsibility, trial practice, and legal writing and research at Hastings College of the Law (1977-83). He received his undergraduate degree from U.C.L.A. in 1973 and his law degree from Boalt Hall School of Law at U.C. Berkeley in 1976.
After retiring from Oracle Corporation Mr. Ocampo helped found and for two years served as Executive Director of the Berkeley Center for Law & Technology, the leading intellectual property program in American law schools. Mr. Ocampo has spoken and written frequently on business and legal issues involving software Internet and computer technologies and has served as a mediator and arbitrator and as an expert witness in technology-related disputes. He has lectured and given keynote addresses at scores of national and international continuing legal education programs and leading law schools and universities, including UCLA, the University of California, Stanford University, Georgetown University, and the Swiss Federal Institute of Technology. His works include Surfing the Law and Technology Tsunami (American Bar Association 2001), a collection of keynote addresses about the intersection of law and technology, and Negotiating and Drafting Software Consulting Agreements (Glasser LegalWorks1996), a book he co-wrote with Shelley Curtis and John Moss.
Mr. Ocampo was the 2001-02 Chair of the American Bar Association's Section of Science & Technology Law. In addition to serving the Section as an officer in various capacities since 1998, he previously served as the chair of the Section's E-Commerce Division (1998-99) and Internet & Cyberspace Committee (1996-99) and as co-chair of the Multimedia & Interactive Technologies Committee (1995-96). He also served as chair of the Computer Litigation Committee (1992-94) of the ABA's Section of Litigation.
Mission Statement
What's New
Management
Business Strategy
Partnerships
Careers
Press
Contact
AI
